| Literature DB >> 35813506 |
Linqian Shao1, Sichao Chen1, Li Ma1.
Abstract
Intracerebral hemorrhage (ICH) is a clinical syndrome in which blood accumulates in the brain parenchyma because of a nontraumatic rupture of a blood vessel. Because of its high morbidity and mortality rate and the lack of effective therapy, the treatment of ICH has become a hot research topic. Meanwhile, Oxidative stress is one of the main causes of secondary brain injury(SBI) after ICH. Therefore, there is a need for an in-depth study of oxidative stress after ICH. This review will discuss the pathway and effects of oxidative stress after ICH and its relationship with inflammation and autophagy, as well as the current antioxidant therapy for ICH with a view to deriving better therapeutic tools or targets for ICH.Entities:
Keywords: Nrf2; cerebral hemorrhage; heme oxygenase; oxidative stress; research progress
Year: 2022 PMID: 35813506 PMCID: PMC9262401 DOI: 10.3389/fncel.2022.853589
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 6.147
Figure 1Sources of oxidative' stress after intracerebral hemorrhage. (1) Activated inflammtory cells include leukocytes, macrophages and microglia. (2) After ICH, glutamate is released into the bloodstream, and glutamate interacts with NMDA receptors, leading to an increase in Ca2+ concentration and thus Ca2+ overload in the mitochondria, which opens the mitochondrial permeability transition pore (MPTP) and disrupts the mitochondrial respiratory chain, resulting in the release of reactive oxygen species. (3) RIRR, ROS-induced ROS release. By Figdraw (www.figdraw.com).
Figure 2Antioxidant mechanism of the Keap1/Nrf2/ARE pathway. When Nrf2 is exposed to reactive oxygen species, it will dissociate from Keap1 and translocate to the nucleus, while activating antioxidant response elements (ARE) that mediate cell survival to drive the expression of Nrf2 target genes for protective purposes. (Created with BioRender.com).
Antioxidant therapy for cerebral hemorrhage.
|
|
|
|
|
|
|---|---|---|---|---|
| MIS surgical treatment | Reduces the excessive production of free radicals such as ROS in the body by expelling blood, thus reducing oxidative damage | In animal studies, neurological function was better protected in animals using MIS alone or in combination with other therapies | Has been tested in clinical trials | Wu et al., |
| Desferrioxamine mesylate (DFO) treatment | Binds to excess iron produced after brain hemorrhage, thereby reducing free radical production and mitigating oxidative damage | Preliminary results from phase II trial show that DFO reduces perihematoma edema | Has been tested in clinical trials | Selim et al., |
| Selenium nanocomposite therapy | Blocking excessive production of intracellular reactive oxygen species, thus reducing oxidative damage after cerebral hemorrhage | Good efficacy for oxidative damage after cerebral hemorrhage was achieved in animal experiments | Has been tested in animal models | Yeatts et al., |
| Nxy-059 treatment | Reduce brain damage by scavenging excess free radicals such as ROS already produced by oxidative stress through neutralization | Did not show significant efficacy | Has been tested in clinical trials | Yang et al., |
| Edaravone treatment | Reduce brain damage by scavenging excess free radicals such as ROS already produced by oxidative stress through neutralization | Recent clinical studies have shown that edaravone does not cause clinically significant QT prolongation as defined by the ICH E14 guidelines for the treatment of patients with cerebral hemorrhage, providing assurance of its safety | Has been tested in clinical trials | Nakamura et al., |
| Combined treatment with N-acetylcysteine and selenium | Reduce brain damage by scavenging excess free radicals such as ROS already produced by oxidative stress through neutralization | Recent clinical studies have shown that this treatment modality slows the progression of perihematomal edema PHE in ICH patients and reduces the time to achieve the target RASS (Richmond Agitation Sedation Scale) and the length of stay in the ICU | Has been tested in clinical trials | Lyden et al., |
| Nrf2 activator carotenoid therapy | Activation of the Nrf2 pathway to enhance antioxidant effects, thereby reducing brain damage from oxidative stress | Radiothione activates Nrf2 in ICH-affected brain tissue and reduces ICH-induced neutrophil counts, oxidative damage, and behavioral defects in animal studies | Has been tested in animal models | Wang et al., |
| Novel Nrf2 activator RS9 therapy | Activation of the Nrf2 pathway to enhance antioxidant effects, thereby reducing brain damage from oxidative stress | The results of the ICH mouse experiment suggest that the activation of Nrf2 by RS9 exerts a neuroprotective effect mediated by the attenuation of oxidative stress | Has been tested in animal models | Shimizu et al., |